Human papillomavirus status of head and neck cancer as determined in cytologic specimens using the hybrid-capture 2 assay.
Human papillomavirus status of head and neck cancer as determined in cytologic specimens using the hybrid-capture 2 assay.
复制标题
DOI：
10.1016/j.oraloncology.2014.02.011
复制
发表时间：
2014-06
期刊：
影响因子：
4.8
通讯作者：
Pai, Sara I.
中科院分区：
文献类型：
--
作者：
Smith, David F.;Maleki, Zahra;Coughlan, Diarmuid;Gooi, Zhen;Akpeng, Belinda;Ogawa, Takenori;Bishop, Justin A.;Frick, Kevin D.;Agrawal, Nishant;Gourin, Christine G.;Ha, Patrick K.;Koch, Wayne M.;Richmon, Jeremy D.;Westra, William H.;Pai, Sara I.
确定头颈部鳞状细胞癌（HNSCC）标本中HPV状态的标准化检测方法尚未建立，特别是细胞学样本。本研究的目的是确定杂交捕获-2 （HC-2）检测是否适用于疑似HNSCCs患者的细胞学标本，该检测已广泛用于检测宫颈刷检中的高危HPV。术前从疑似HNSCCs患者处获得颈部淋巴结细针抽吸（FNA），并使用HC-2检测评估HPV的存在。采用p16免疫组化（IHC）和HR-HPV原位杂交（ISH）对相应的切除组织标本进行HPV分析。使用医疗保险和医疗补助服务中心进行成本分析。在84%（21/25）的病例中，使用HC-2检测可以正确分类宫颈淋巴结转移的HPV状态。当细胞学评估证实测试样本中存在癌细胞时，准确性提高到100%。使用HC-2检测对CMS的估计成本节约范围为每位患者113.74美元至364.63美元。HC-2是确定HNSCCs中HPV状态的可靠方法。它在HNSCCs中的应用可以降低成本，因为它有助于在诊断过程中定位原发部位，并减少确定HPV状态的间隔时间，这将有助于为患者提供预后信息，并确定针对这一独特患者群体的临床试验资格。
A standardized assay to determine the HPV status of head and neck squamous cell carcinoma (HNSCC) specimens has not yet been established, particularly for cytologic samples. The goal of this study was to determine whether the hybrid capture-2 (HC-2) assay, already widely used for the detection of high risk HPV in cervical brushings, is applicable to cytologic specimens obtained from patients with suspected HNSCCs. Fine needle aspirates (FNA) of cervical lymph nodes were pre-operatively obtained from patients with suspected HNSCCs and evaluated for the presence of HPV using the HC-2 assay. HPV analysis was performed on the corresponding resected tissue specimens using p16 immunohistochemistry (IHC) and HR-HPV in situ hybridization (ISH). A cost analysis was performed using the Center for Medicare & Medicaid Services. HPV status of the cervical lymph node metastases was correctly classified using the HC-2 assay in 84% (21/25) of cases. Accuracy was improved to 100% when cytologic evaluation confirmed the presence of cancer cells in the test samples. The estimated cost savings to CMS using the HC-2 assay ranged from $113.74 to $364.63 per patient. HC-2 is a reliable method for determining the HPV status of HNSCCs. Its application to HNSCCs may reduce costs by helping to localize the primary site during the diagnostic work-up as well as decrease the interval time of determining the HPV status which would be relevant for providing prognostic information to the patient as well as determining eligibility for clinical trials targeting this unique patient population.
登录
查看更多内容
影响因子：
10.3
作者：
Schwartz, SM;Daling, JR;Galloway, DA
通讯作者：
Galloway, DA
DOI：
10.1056/nejmoa0912217
发表时间：
2010-07-01
期刊：
The New England journal of medicine
影响因子：
--
作者：
Ang KK;Harris J;Wheeler R;Weber R;Rosenthal DI;Nguyen-Tân PF;Westra WH;Chung CH;Jordan RC;Lu C;Kim H;Axelrod R;Silverman CC;Redmond KP;Gillison ML
通讯作者：
Gillison ML
影响因子：
3.4
作者：
Bishop, Justin A.;Maleki, Zahra;Westra, William H.
通讯作者：
Westra, William H.
影响因子：
45.3
作者：
Licitra, Lisa;Perrone, Federica;Pilotti, Silvana
通讯作者：
Pilotti, Silvana
影响因子：
11.5
作者：
Begum, Shahnaz;Gillison, Maura L.;Westra, William H.
通讯作者：
Westra, William H.